Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Chimerix (NASDAQ:CMRX), a biopharmaceutical company, announced on August 30, 2024, that its Compensation Committee granted an inducement award to a new employee. The award consists of non-statutory stock options to purchase up to 150,000 shares of Chimerix's common stock. The stock options have a 10-year term and will vest over four years, with one-fourth vesting on the one-year anniversary of hire and the remaining three-fourths vesting monthly over the following three years. The exercise price is equal to Chimerix's closing trading price on the grant date. This award was approved in accordance with Nasdaq Listing rule 5635(c)(4) and is subject to the terms of Chimerix's 2024 Equity Incentive Plan, although granted outside of it.
Chimerix (NASDAQ:CMRX), un'azienda biofarmaceutica, ha annunciato il 30 agosto 2024 che il suo Comitato Compensi ha concesso un premio di incentivazione a un nuovo dipendente. Il premio consiste in opzioni su azioni non statutarie per l'acquisto di fino a 150.000 azioni delle azioni ordinarie di Chimerix. Le opzioni su azioni hanno un termine di 10 anni e matureranno in quattro anni, con un quarto che matura al primo anniversario dell'assunzione e i restanti tre quarti che maturano mensilmente nei seguenti tre anni. Il prezzo di esercizio è pari al prezzo di chiusura delle azioni di Chimerix alla data di concessione. Questo premio è stato approvato in conformità con la regola di quotazione Nasdaq 5635(c)(4) ed è soggetto ai termini del Piano di Incentivi in Azioni 2024 di Chimerix, sebbene concesso al di fuori di esso.
Chimerix (NASDAQ:CMRX), una empresa biofarmacéutica, anunció el 30 de agosto de 2024 que su Comité de Compensación otorgó un premio de incentivación a un nuevo empleado. El premio consiste en opciones de acciones no estatutarias para la compra de hasta 150,000 acciones de las acciones ordinarias de Chimerix. Las opciones de acciones tienen un plazo de 10 años y se vestirá en cuatro años, con un cuarto que se otorgará en el primer aniversario de la contratación y los tres cuartos restantes que se otorgarán mensualmente durante los siguientes tres años. El precio de ejercicio es igual al precio de cierre de Chimerix en la fecha de otorgamiento. Este premio fue aprobado de acuerdo con la regla de cotización 5635(c)(4) de Nasdaq y está sujeto a los términos del Plan de Incentivos en Acciones 2024 de Chimerix, aunque se otorgó fuera de este.
Chimerix (NASDAQ:CMRX), 생명공학 회사는 2024년 8월 30일 새로운 직원에게 유인 상을 부여했다는 것을 발표했습니다. 이 상은 최대 150,000주의 주식을 구매할 수 있는 비법적 주식 옵션으로 구성되어 있습니다. 주식 옵션은 10년 기간을 가지며 4년에 걸쳐 분할 지급됩니다, 첫 해 기념일에 1/4이 지급되고 나머지 3/4는 다음 3년 동안 매달 지급됩니다. 행사가격은 부여 날짜의 Chimerix의 종가와 동일합니다. 이 상은 Nasdaq 상장 규칙 5635(c)(4)에 따라 승인되었으며 Chimerix의 2024년 주식 인센티브 계획의 조건을 따릅니다. 다만, 해당 계획 외부에서 부여되었습니다.
Chimerix (NASDAQ:CMRX), une entreprise biopharmaceutique, a annoncé le 30 août 2024 que son Comité de Rémunération a accordé une prime d'incitation à un nouvel employé. La prime se compose de stock-options non statutaires pour l'achat de jusqu'à 150 000 actions des actions ordinaires de Chimerix. Les options d'achat d'actions ont une durée de 10 ans et s'acquitteront sur quatre ans, un quart s'acquittant à la première anniversary de l'embauche et les trois quarts restants s'acquittant mensuellement au cours des trois années suivantes. Le prix d'exercice est égal au prix de clôture de Chimerix à la date d'attribution. Cette prime a été approuvée conformément à la règle de cotation Nasdaq 5635(c)(4) et est soumise aux modalités du Plan d'Incentives en Actions 2024 de Chimerix, bien qu'elle ait été accordée en dehors de celui-ci.
Chimerix (NASDAQ:CMRX), ein biopharmazeutisches Unternehmen, gab am 30. August 2024 bekannt, dass sein Vergütungsausschuss einem neuen Mitarbeiter eine Anreizprämie gewährt hat. Die Prämie besteht aus nicht-statutären Aktienoptionen zum Kauf von bis zu 150.000 Aktien der Stammaktien von Chimerix. Die Aktienoptionen haben eine Laufzeit von 10 Jahren und werden über vier Jahre fällig, wobei ein Viertel am ersten Jahrestag der Einstellung und die verbleibenden drei Viertel monatlich in den folgenden drei Jahren fällig werden. Der Ausübungspreis entspricht dem Schlusskurs von Chimerix am Tag der Gewährung. Diese Prämie wurde gemäß der Nasdaq-Listing-Regel 5635(c)(4) genehmigt und unterliegt den Bedingungen des Equity Incentive Plans 2024 von Chimerix, obwohl sie außerhalb dieses Plans gewährt wurde.
- Attraction of new talent with stock options as incentive
- Alignment of employee interests with company performance through equity grants
- Potential dilution of existing shareholders' equity
DURHAM, N.C., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on August 20, 2024, the Compensation Committee of Chimerix’s Board of Directors granted an inducement award to a new employee of non-statutory stock options to purchase up to a total of 150,000 shares of Chimerix’s common stock. The Compensation Committee of Chimerix’s Board of Directors approved the award as an inducement material to the new employee’s employment in accordance with Nasdaq Listing rule 5635(c)(4).
The stock options have an exercise price per share equal to Chimerix’s closing trading price as of the grant date. The stock options have a 10-year term and will vest over four years, with one-fourth vesting on the one-year anniversary of the date of hire and the remaining three-fourths vesting over the following three years in equal monthly installments. The stock options are subject to the terms of Chimerix’s 2024 Equity Incentive Plan but were granted outside of the 2024 Equity Incentive Plan.
Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma. The Company is conducting Phase 1 dose escalation studies of ONC206 to evaluate safety and PK data.
CONTACTS:
Will O’Connor
Stern Investor Relations
212-362-1200
ir@chimerix.com
will@sternir.com
FAQ
How many shares of Chimerix (CMRX) stock options were granted to the new employee?
What is the vesting schedule for the stock options granted by Chimerix (CMRX) on August 20, 2024?
What is the exercise price of the stock options granted by Chimerix (CMRX)?
Under which Nasdaq rule did Chimerix (CMRX) grant the inducement award?
